I N Micallef, A Kirk, A Norton, J M Foran, A Z Rohatiner, T A Lister. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » Antibodies, Monoclonal/adverse effectsAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, Murine-DerivedAntigens, CD20/immunologyAntigens, Neoplasm/immunologyAntineoplastic Combined Chemotherapy Protocols/adverse effectsAntineoplastic Combined Chemotherapy Protocols/therapeutic useCombined Modality Therapy/adverse effectsFatal OutcomeHumansImmunophenotypingImmunotherapy/adverse effectsLymphoma, Large B-Cell, Diffuse/drug therapyLymphoma, Large B-Cell, Diffuse/radiotherapyLymphoma, Large B-Cell, Diffuse/therapyLymphoma, Non-Hodgkin/drug therapyLymphoma, Non-Hodgkin/radiotherapyLymphoma, Non-Hodgkin/therapyLymphoma, T-Cell, Peripheral/etiologyMaleMiddle AgedNeoplasms, Second Primary/etiologyRituximab
Substances： See more » Antibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD20Antigens, NeoplasmRituximab
Year: 1999 PMID： 10215354
Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113